The transactions highlighted below are representative of Greenhill engagements. In addition, the Firm has completed many engagements that were not publicly-disclosed.
Recent Transactions
Sort By
![USA/UK U.S.A., U.K. flags](https://www.greenhill.com/sites/default/files/usa_uk.gif)
US rights to Toprol-XL (AstraZeneca)
![Canada Canada flag](https://www.greenhill.com/sites/default/files/canada.gif)
Advised Aralez Pharmaceuticals Inc., a global specialty pharmaceutical company in connection with the financing of its acquisition of the US rights to cardiovascular drug Toprol-XL (metoprolol succinate) and its Authorized Generic from AstraZeneca.
![Australia Australia flag](https://www.greenhill.com/sites/default/files/australia.gif)
GrainCorp Limited
![United States United States flag](https://www.greenhill.com/sites/default/files/usa_0.gif)
Advised GrainCorp Limited on the unsolicited takeover offer from Archer Daniels Midland Company, a global agribusiness that converts oilseeds, corn, wheat and cocoa into products for food, animal feed and energy uses
![United States United States flag](https://www.greenhill.com/sites/default/files/usa_0.gif)
ISTA Pharmaceuticals, Inc.
Advised ISTA Pharmaceuticals, an ophthalmic pharmaceutical company, on its defense against an unsolicited offer from Valeant Pharmaceuticals and on its review of strategic alternatives
![United States United States flag](https://www.greenhill.com/sites/default/files/usa_0.gif)
Wesco Financial Corporation
![United States United States flag](https://www.greenhill.com/sites/default/files/usa_0.gif)
Advised the Special Committee of Wesco Financial Corporation in connection with Berkshire Hathaway Inc.'s proposal to acquire the remaining 19.9% of the shares of Wesco’s common stock that it does not presently own
![USA/Switzerland U.S.A., Swiss flags](https://www.greenhill.com/sites/default/files/usa_swiss.gif)
Alcon, Inc.
![Switzerland Switzerland flag](https://www.greenhill.com/sites/default/files/switzerland.gif)
Advised the Independent Director Committee of Alcon, Inc., an ophthalmic pharmaceutical company, on the sale of Alcon’s outstanding publicly held interest to Novartis AG, a global pharmaceutical company